Condition
Leucogen
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 3 (1)
Trial Status
Not Yet Recruiting1
Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07380646Phase 2RecruitingPrimary
the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer
NCT05780294Phase 3Not Yet Recruiting
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
Showing all 2 trials